InSilico Medicine Receives Seed Funding from Deep Knowledge Ventures

InSilico Medicine, Inc. a Baltimore, Maryland-based developer of a drug knowledge management system of annotated drugs, small molecules, biologics available, received a seed funding from Deep Knowledge Ventures.

The amount of the deal was not disclosed.

Led by CEO Professor Alex Zhavoronkov, PhD, InSilico Medicine has been developing a comprehensive scalable drug knowledge management system of annotated drugs, small molecules, biologics available. The company aims to partner with top pharmaceutical companies to help analyze their drug databases and lead compounds, improve enrollment into clinical trials, and to enable them to accurately predict the efficacy of their drugs on patient groups and individual patients.

FinSMEs

16/04/2014

Join the discussion